Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

First Posted Date
2023-03-20
Last Posted Date
2023-03-20
Lead Sponsor
Chongqing University Cancer Hospital
Target Recruit Count
12
Registration Number
NCT05776407
Locations
🇨🇳

Chongqing University Cancer Hospital, Chongqing, Chongqing, China

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

First Posted Date
2023-03-14
Last Posted Date
2024-07-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
20
Registration Number
NCT05767359
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

First Posted Date
2023-03-07
Last Posted Date
2024-11-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
6
Registration Number
NCT05757310
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

First Posted Date
2023-03-06
Last Posted Date
2023-09-22
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
10
Registration Number
NCT05755854
Locations
🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

First Posted Date
2023-03-02
Last Posted Date
2024-06-21
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
26
Registration Number
NCT05751044
Locations
🇳🇱

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

First Posted Date
2023-02-27
Last Posted Date
2024-06-21
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
26
Registration Number
NCT05745714
Locations
🇳🇱

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

First Posted Date
2023-02-21
Last Posted Date
2024-05-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
24
Registration Number
NCT05736419
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States

and more 3 locations

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

First Posted Date
2023-02-06
Last Posted Date
2024-05-31
Lead Sponsor
Allogene Therapeutics
Target Recruit Count
70
Registration Number
NCT05714345
Locations
🇧🇪

Universitair Ziekenhuis Brussel, Brussel, Belgium

🇺🇸

University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

First Posted Date
2023-01-31
Last Posted Date
2024-06-18
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
21
Registration Number
NCT05707273
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

First Posted Date
2023-01-31
Last Posted Date
2023-01-31
Lead Sponsor
Hospital Israelita Albert Einstein
Target Recruit Count
30
Registration Number
NCT05705570
Locations
🇧🇷

Hospital Israelita Albert Einstein, São Paulo, Brazil

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy